Regulatory News
Thursday, April 28, 2016
Acadia drug approval could clear way for Axovant dementia therapy
April 28 (Reuters) - An imminent ruling on Acadia
Pharmaceuticals Inc's drug for Parkinson's disease
psychosis is being closely watched by a Bermuda-based company
with a similar treatment for...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment